BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 6, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2022

View Archived Issues
Tumor microenvironment

Cancer cells use, impersonate neurons to grow

Two studies published this week have reported new insights into the role of the nervous system in tumors outside of the brain. Researchers at the Shanghai Jiao Tong University School of Medicine have identified a role for pain-sensing neurons in helping oral carcinomas cope with nutrient starvation, and that this interaction could be blocked by the calcitonin gene-related peptide (CGRP)-targeting migraine drug Nurtec ODT (rimegepant; Biohaven Pharmaceutical Holding Co. Ltd.). Read More

Long lung COVID gives broader insights into fibrotic lung disease

An in-depth investigation of the underlying causes of pulmonary symptoms that in some cases persist for months following recovery from the acute stage of COVID-19 has found a distinctive proinflammatory signature in the plasma and airways of affected patients. The research could provide an explanation for the ongoing interstitial lung disease and fibrosis seen in patients who were hospitalized with severe COVID-19, and also point to neutrophils as a specific therapeutic target. Read More
Joint pain

NIP-322: a novel treatment for osteoarthritis pain

Increased levels of tetrahydrobiopterin (BH4) are linked to pain sensitivity in humans... Read More
Central nervous system

RTI-122 as a potent GPR88 agonist for CNS-related disorders

RTI International has presented results on RTI-122, a G protein-coupled receptor 88... Read More

Novel autophagic flux inhibitor shows efficacy in models of TNBC

A research team based at Chongqing University of Arts and Sciences has described... Read More
3D representation of tumor microenvironment

Parthenon Therapeutics targets DDR1 with lead asset PRTH-101 to treat immune-excluded tumors

Parthenon Therapeutics Inc. has unveiled its precision medicine approach designed... Read More

Mindset Pharma presents preclinical data on MSP-1014

Psilocybin is a prodrug of psilocin, which is thought to mediate antidepressant effects... Read More

Insusense patents new sortilin receptor-targeting compounds

Insusense ApS has divulged drugs targeting sortilin receptor reported to be useful... Read More
Cancer cells being destroyed by immunotherapy

Anti-EPN1 antibody enhances the efficacy of anti-PD-L1 therapy in model of melanoma

Epsin 1 (EPN1) is an adapter protein involved in clathrin-mediated endocytosis and upregulated in multiple cancers. Read More

Pfizer and Biontech advance next-generation COVID-19 vaccine candidate into clinic

Pfizer Inc. and Biontech SE have initiated a phase I study to evaluate the safety, tolerability and immunogenicity of BNT-162b4, a next-generation COVID-19 vaccine candidate that aims to enhance SARS-CoV-2 T-cell responses and potentially broaden protection against COVID-19. Read More

Nihon Medi-Physics has disclosed new ADCs for cancer

Nihon Medi-Physics Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising a peptide-modified antibody targeting B-lymphocyte antigen CD20 covalently linked to a radionuclide-chelating agent through a linker reported to be useful for the diagnosis and treatment of cancer. Read More
Brain and encephalography

CACNB3 as novel therapeutic target in mesial temporal lobe epilepsy

Investigators at the University of Copenhagen and affiliated organizations presented data from a study that aimed to validate differentially expressed genes (DEGs) in mesial temporal lobe epilepsy (mTLE) as potential new targets. Read More

Merck Sharp & Dohme describes new KLKB1 inhibitors

Merck Sharp & Dohme Corp. has disclosed plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema, diabetic macular edema, retinal vein occlusion, wet macular degeneration (exudative) and uveitis. Read More

US researchers divulge new NOX inhibitors

Emory University and Medical College of Wisconsin have presented quinazolinone derivatives acting as NADPH oxidase (NOX) inhibitors reported to be useful for the treatment of traumatic brain injury and epilepsy. Read More
Nanoparticles in cancer cells.

Sunshine Biopharma collaborates to advance LNP formulation of its antineoplastic mRNA K1.1

Sunshine Biopharma Inc. has entered into a collaboration agreement with a leading lipid nanoparticle (LNP) formulation company to advance the development of Sunshine's mRNA-based anticancer macromolecule, K1.1. Read More

Yuhan has synthesized new AOC3 inhibitors

Yuhan Corp. has patented membrane primary amine oxidase (AOC3) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis. Read More

Other news to note for Nov. 17, 2022

Additional early-stage research and drug discovery news in brief, from: Athira, Biovaxys. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • Janssen Pharmaceutica reports new TMEM175 activators

    BioWorld Science
    Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing